Alex Spira, MD, PhD, FACP Presenting Author and Contributing author for multiple presentations for the 2020 World Conference on Lung Cancer – January 28 – 31, 2021
https://library.iaslc.org/search-speaker?search_speaker=87361
FP02 – Health Services Research/Health Economics
- Event: WCLC 2020
- Type: Posters (Featured)
- Track: Health Services Research/Health Economics
- Presentations: 1
FP02.02 – Real-World Outcomes Among Advanced Non-Small Cell Lung Cancer Patients Re-Treated with Immunotherapy in the US
00:00 – 00:00 | Presenting Author(s): Alex I. Spira
OA03 – Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC
- Event: WCLC 2020
- Type: Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Presentations: 1
OA03.03 – Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study (ID 3407)
10:30 – 11:30 | Presenting Author(s): Alex I. Spira
1/29/2021, 10:30 – 11:30, Scientific Program Auditorium
OA04 – New Data from Rare EGFR Alterations
- Event: WCLC 2020
- Type: Oral
- Track: Targeted Therapy – Clinically Focused
- Presentations: 1
P01 – Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Event: WCLC 2020
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Presentations: 1
P01.06 – CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase
00:00 – 00:00 | Author(s): Alex I. Spira
1/28/2021, 00:00 – 00:00, ePoster Hall
P77 – Immunotherapy (Phase II/III Trials) – Combining Different Immunotherapeutic Approaches
- Event: WCLC 2020
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 1
77.02 – Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
00:00 – 00:00 | Author(s): Alex I. Spira
1/28/2021, 00:00 – 00:00, ePoster Hall
P90 – Targeted Therapy – Clinically Focused – Misc. Topics
- Event: WCLC 2020
- Type: Posters
- Track: Targeted Therapy – Clinically Focused
- Presentations: 1
P90.03 – A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (ID 2968)
00:00 – 00:00 | Presenting Author(s): Alex I. Spira
PS01 – Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- Event: WCLC 2020
- Type: Plenary
- Track: N.A.
Presentations: 1
PS01.07 – CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer (ID 3037)
07:00 – 09:00 | Author(s): Alex I. Spira
PS02 – Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available) (ID 275)
- Event: WCLC 2020
- Type: Plenary
- Track: N.A.
- Presentations: 1
PS02.07 – CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer (ID 4290)
18:00 – 20:00 | Author(s): Alex I. Spira
